Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)

NCT04938830 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1003

Enrollment

INDUSTRY

Sponsor class

Conditions

RSV Infection

Interventions

BIOLOGICAL: Clesrovimab
BIOLOGICAL: Palivizumab
BIOLOGICAL: Placebo

Sponsor

Merck Sharp & Dohme LLC